. Author manuscript; available in PMC: 2017 Dec 14.

Published in final edited form as: Eur J Endocrinol. 2015 Jan 30;172(5):527–535. doi: 10.1530/EJE-14-0877

Table 2.

Exposure of subjects to study drug in double-blind phase (weeks 1–28).


	Cinacalcet (n = 33)	Placebo (n = 34)

Total duration of exposure (months)
Mean	5.83	5.83
s.e.m.	0.32	0.30
Median	6.47	6.44
Q1, Q3	6.41, 6.54	6.41, 6.51
Min, max	0.7, 7.0	0.0, 6.7
Average daily dose or equivalent (mg/day)
Mean	82.7	176.8^a
s.e.m.	8.1	10.5^a
Median	60.2	203.9^a
Q1, Q3	59.1, 110.3	157.2, 219.4^a
Min, max	17, 212	6, 228^a

n = 33; excludes one subject who did not return bottle of investigational product and it is unknown how many tablets the subject took.